Earnings Call Intelligence Subscribe
Home › Call Sheets › IDXX › Q1'26
Call sheet · Q1'26

IDEXX Laboratories (IDXX)

Q1'26 earnings call · held May 5, 2026 · compared with the Q4'25 call · management-credibility review
10/12
Disclosure score
2 medium, 5 low flags
Financial quality
Bottom line
The sleeper story is aging pandemic pets hitting an inflection point - IDEXX is getting 1,100 basis points of premium to declining visits because pets 5+ years old are driving both sick and wellness visits higher for the third straight quarter. This demographic shift is worth more than any single product launch. The obvious headline is the guidance raise and strong Q1 execution, but the real story is this demographic tailwind is durable and expanding. The binding constraint isn't demand - it's IDEXX's ability to scale commercial coverage to capitalize on international opportunities where diagnostics penetration is still early stage. Most revealing quote from Jay: 'Non-well visits represent about 60% of visits, but 70-75% of diagnostics revenue' - this mix shift matters more than total visit recovery. My view changes if the aging pet trend stalls or if InVue utilization metrics start declining from current 'well within' range levels.

The 30-second version

  • SLEEPER: Aging pandemic pets are hitting the inflection point on non-well visits - this is worth 1,100 basis points of premium to visit declines
  • InVue momentum real but F&A rollout language got more cautious - they're managing expectations down
  • Visit guide 'improvement' is smoke and mirrors - they just updated the baseline to match reality

What changed this quarter

MetricQ4'25Q1'26Change
Revenue Growth14% reported, 12% organic14% reported, 11% organic100 bps organic deceleration
CAG Diagnostics Recurring10% organic growth11% organic growth+100 bps acceleration
US Same-Store Visits-1.7% decline Q4-1% decline Q170 bps improvement
Non-Well VisitsFlat to slightly negative+20 bps growthPositive inflection
Wellness Visits-3.6% Q4-3% Q160 bps less bad
VetLab Consumables15% organic growth15% organic growthMaintained momentum
InVue Placements1,900 units Q41,100 units Q1Normal seasonal step-down
Premium Instrument Installed Base12% growth12% growthSustained double-digit expansion
Reference Lab Revenue9% organic growth10% organic growth+100 bps acceleration
Rapid Assay Revenue-3% organic declineFlat organic300 bps improvement

Accountability tracked

8 new promises made4 narrative shifts flagged7 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full IDXX Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.